España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Amicus Therapeutics
FOLD
NASDAQ
Watchlist
Get Report
Perks
Buy
Compare Brokers
$10.02
0.21
2.14%
At Close: -
$10.02
0
0.00%
After Hours: Jul 5, 4:00 PM EDT
15 minutes delayed
Get Report
Watch
Amicus Therapeutics (FOLD) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Amicus Therapeutics (NASDAQ:FOLD) Stock
Amicus Therapeutics Stock (NASDAQ: FOLD)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, May 30, 2024
Wells Fargo Initiates Coverage On Amicus Ther...
Benzinga Newsdesk
Tuesday, May 14, 2024
Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
Benzinga Insights
This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today.
Avi Kapoor
Amicus Therapeutics shares are trading higher...
Benzinga Newsdesk
Guggenheim Upgrades Amicus Therapeutics to Bu...
Benzinga Newsdesk
Friday, May 10, 2024
UBS Maintains Buy on Amicus Therapeutics, Low...
Benzinga Newsdesk
Morgan Stanley Maintains Overweight on Amicus...
Benzinga Newsdesk
B of A Securities Maintains Buy on Amicus The...
Benzinga Newsdesk
Needham Reiterates Hold on Amicus Therapeutic...
Benzinga Newsdesk
Thursday, May 09, 2024
Amicus Therapeutics shares are trading lower ...
Benzinga Newsdesk
Amicus Forecasts 2024 Total Revenue Growth Of...
Benzinga Newsdesk
Amicus Therapeutics Q1 2024 Adj EPS $(0.02) B...
Benzinga Newsdesk
Monday, March 18, 2024
JP Morgan Maintains Overweight on Amicus Ther...
Benzinga Newsdesk
Thursday, February 29, 2024
Cantor Fitzgerald Reiterates Overweight on Am...
Benzinga Newsdesk
Wednesday, February 28, 2024
Amicus Therapeutics Projects 2024 Galafold Re...
Benzinga Newsdesk
Amicus Therapeutics Q4 Adj EPS $0.01 Beats $(...
Benzinga Newsdesk
Earnings Scheduled For February 28, 2024
Benzinga Insights
Thursday, February 08, 2024
Amicus Therapeutics Says It Received 2024 New...
Benzinga Newsdesk
Sunday, January 07, 2024
Amicus Therapeutics Reports Preliminary 2023 ...
Benzinga Newsdesk
Tuesday, December 19, 2023
The Analyst Landscape: 4 Takes On Amicus Therapeutics
Benzinga Insights
Morgan Stanley Upgrades Amicus Therapeutics t...
Benzinga Newsdesk
Tuesday, December 05, 2023
Amicus Therapeutics' John Crowley, Executive ...
Benzinga Newsdesk
Thursday, November 09, 2023
Morgan Stanley Maintains Equal-Weight on Amic...
Benzinga Newsdesk
Wednesday, November 08, 2023
Amicus Therapeutics Is On-Track To Achieve No...
Benzinga Newsdesk
For FY23, Amicus Therapeutics Is Increasing G...
Benzinga Newsdesk
Amicus Therapeutics Q3 EPS $(0.07) Beats $(0....
Benzinga Newsdesk
Earnings Scheduled For November 8, 2023
Benzinga Insights
Tuesday, October 10, 2023
Morgan Stanley Maintains Equal-Weight on Amic...
Benzinga Newsdesk
Monday, October 02, 2023
Amicus Therapeutics And Blackstone Enter Into...
Benzinga Newsdesk
Friday, September 29, 2023
JP Morgan Maintains Overweight on Amicus Ther...
Benzinga Newsdesk
Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session
Lisa Levin
Thursday, September 28, 2023
Amicus Therapeutics Drug Scores FDA Approval For Rare Inherited Pompe Disease
Vandana Singh
Amicus Therapeutics Shares Resume Trade
Benzinga Newsdesk
Amicus Therapeutics, Inc. Shares To Resume Tr...
Benzinga Newsdesk
Amicus Therapeutics Announces FDA Approval An...
Benzinga Newsdesk
Amicus Therapeutics Shares Halted, News Pendi...
Benzinga Newsdesk
Monday, August 21, 2023
Amicus Therapeutics Appoints Simon Harford As...
Benzinga Newsdesk
Tuesday, August 15, 2023
Amicus Therapeutics Announces Approval And La...
Benzinga Newsdesk
Tuesday, August 08, 2023
Amicus Therapeutics shares are trading higher...
Bill Haddad
Amicus Therapeutics Q2 EPS $(0.15) Misses $(0...
Benzinga Newsdesk
Earnings Scheduled For August 8, 2023
Benzinga Insights
Tuesday, July 11, 2023
Morgan Stanley Reiterates Equal-Weight on Ami...
Benzinga Newsdesk
Monday, June 26, 2023
Amicus Therapeutics Gets European Commission Approval Of Opfolda For The Treatment Of Adults Living With Late-Onset Pompe Disease.
Happy Mohamed
Wednesday, May 10, 2023
Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics
Vandana Singh
Earnings Scheduled For May 10, 2023
Benzinga Insights
Amicus Therapeutics Expects FY23 Galafold Rev...
Benzinga Newsdesk
Amicus Therapeutics: Q1 Earnings Insights
Benzinga Insights
Amicus Therapeutics Q1 EPS $(0.18) Misses $(0...
Benzinga Newsdesk
Wednesday, April 26, 2023
Amicus Therapeutics Receives Positive Committee For Medicinal Products For Human Use Opinion For Opfolda For Late-Onset Pompe Disease
Happy Mohamed
Monday, April 24, 2023
Amicus Therapeutics On Apr. 18 Entered Supply...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch